Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.72.

A number of equities research analysts have recently weighed in on the company. Wedbush restated an “outperform” rating and set a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Monday, January 27th. Finally, Cantor Fitzgerald started coverage on Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company.

Voyager Therapeutics Trading Up 1.7 %

Voyager Therapeutics stock opened at $4.08 on Friday. Voyager Therapeutics has a 12-month low of $3.91 and a 12-month high of $10.66. The firm has a 50 day moving average of $5.18 and a 200 day moving average of $6.01. The firm has a market capitalization of $222.87 million, a price-to-earnings ratio of 5.75 and a beta of 0.91.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after acquiring an additional 6,740 shares in the last quarter. FMR LLC increased its stake in Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after acquiring an additional 19,622 shares during the last quarter. Barclays PLC increased its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after acquiring an additional 37,398 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Voyager Therapeutics during the third quarter worth about $216,000. Finally, Erste Asset Management GmbH acquired a new stake in Voyager Therapeutics during the third quarter worth about $6,192,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.